TY - JOUR
T1 - Opposing roles of IL-10 in acute bacterial infection
AU - Peñaloza, Hernán F.
AU - Schultz, Barbara M.
AU - Nieto, Pamela A.
AU - Salazar, Geraldyne A.
AU - Suazo, Isidora
AU - Gonzalez, Pablo A.
AU - Riedel, Claudia A.
AU - Alvarez-Lobos, Manuel M.
AU - Kalergis, Alexis M.
AU - Bueno, Susan M.
N1 - Funding Information:
Manuel M. Alvarez-Lobos is an associate professor in the Department of Gastroenterology at the Pontificia Universidad Católica de Chile (PUCC). He is a MD from PUCC (1994) and he obtained the specialty in internal medicine (1997) and gastroenterology subspecialty (1999) at the same university. Later, he did his postgraduate training at Inflammatory bowel disease Unit in Hospital Clinic of Barcelona, Spain, from 2002 to 2004. He is a member of the Gastroenterology Chilean Society. Dr. Alvarez-Lobos directs the Laboratory of Intestinal diseases. His research interests comprise intestinal infectious diseases and inflammatory bowel disease. These research projects have been funded by FONDECYT, FONDEF and FONIS. He has published more than 50 articles.
Funding Information:
Dr. Alexis M. Kalergis is full professor at the School of Biological Sciences and Medicine of the PUCC. He obtained the Julius Marmur Award for his MSc and PhD work on Microbiology and Immunology at the Albert Einstein College of Medicine in New York. He performed post-doctoral training at the AECM and The Rockefeller University, supported by the Helen Hay Whitney Foundation. He has trained over a hundred young scientists, lectured countless conferences and published over 140 articles. He is a member of the American Society of Immunology, the American Society of Microbiology and the Chilean Societies for Biology, Cell Biology and Immunology. He was selected as the most outstanding young scientist by the Biology Society of Chile, as one of the fifty Chilean young leaders and awarded several important national and international research grants. He is the Director of the Millennium Institute on Immunology and Immunotherapy, a Research Excellence Center that was recently selected as a FOCIS Center of Excellence in the USA. He created a Consortium on Biomedicine, which is the largest grant on this area awarded to a University-Company alliance in Chile. His group has recently developed a new vaccine against HRSV, currently in clinical trials. His research focuses on the molecular interactions regulating the T cell-DC synapse and their contribution to pathogen immunity and self-tolerance during autoimmunity.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Interleukin-10 (IL-10) is recognized as an anti-inflammatory cytokine that downmodulates inflammatory immune responses at multiple levels. In innate cells, production of this cytokine is usually triggered after pathogen recognition receptor (PRR) engagement by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patters (DAMPs), as well as by other soluble factors. Importantly, IL-10 is frequently secreted during acute bacterial infections and has been described to play a key role in infection resolution, although its effects can significantly vary depending on the infecting bacterium. While the production of IL-10 might favor host survival in some cases, it may also result harmful for the host in other circumstances, as it can prevent appropriate bacterial clearance. In this review we discuss the role of IL-10 in bacterial clearance and propose that this cytokine is required to recover from infection caused by extracellular or highly pro-inflammatory bacteria. Altogether, we propose that IL-10 drives excessive suppression of the immune response upon infection with intracellular bacteria or in non-inflammatory bacterial infections, which ultimately favors bacterial persistence and dissemination within the host. Thus, the nature of the bacterium causing infection is an important factor that needs to be taken into account when considering new immunotherapies that consist on the modulation of inflammation, such as IL-10. Indeed, induction of this cytokine may significantly improve the host's immune response to certain bacteria when antibiotics are not completely effective.
AB - Interleukin-10 (IL-10) is recognized as an anti-inflammatory cytokine that downmodulates inflammatory immune responses at multiple levels. In innate cells, production of this cytokine is usually triggered after pathogen recognition receptor (PRR) engagement by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patters (DAMPs), as well as by other soluble factors. Importantly, IL-10 is frequently secreted during acute bacterial infections and has been described to play a key role in infection resolution, although its effects can significantly vary depending on the infecting bacterium. While the production of IL-10 might favor host survival in some cases, it may also result harmful for the host in other circumstances, as it can prevent appropriate bacterial clearance. In this review we discuss the role of IL-10 in bacterial clearance and propose that this cytokine is required to recover from infection caused by extracellular or highly pro-inflammatory bacteria. Altogether, we propose that IL-10 drives excessive suppression of the immune response upon infection with intracellular bacteria or in non-inflammatory bacterial infections, which ultimately favors bacterial persistence and dissemination within the host. Thus, the nature of the bacterium causing infection is an important factor that needs to be taken into account when considering new immunotherapies that consist on the modulation of inflammation, such as IL-10. Indeed, induction of this cytokine may significantly improve the host's immune response to certain bacteria when antibiotics are not completely effective.
KW - Acute bacterial infection
KW - Extracellular bacteria
KW - Inflammation severity
KW - Innate immunity
KW - Interleukin-10
KW - Intracellular bacteria
UR - http://www.scopus.com/inward/record.url?scp=84994257590&partnerID=8YFLogxK
U2 - 10.1016/j.cytogfr.2016.07.003
DO - 10.1016/j.cytogfr.2016.07.003
M3 - Short survey
AN - SCOPUS:84994257590
SN - 1359-6101
VL - 32
SP - 17
EP - 30
JO - Cytokine and Growth Factor Reviews
JF - Cytokine and Growth Factor Reviews
ER -
